Videos

Belinda Ostrowsky, MD, MPH, Health Systems Director of Epidemiology, Antimicrobial Stewardship & Infection Prevention, Montefiore Medical Center, and Associate Professor of Clinical Medicine, Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, explains how to be more sensible when it comes to testing for Clostridium difficile.

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, explains the best ways to reduce the number of respiratory viral healthcare-associated infections in children.

Snigdha Vallabhaneni, MD, MPH, Medical Epidemiologist, Mycotic Diseases Branch at the Centers for Disease Control and Prevention, discusses the threat that is Candida auris.

Nimalie Stone, MD, MS, Team Lead, LTC, Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention, explores the differences in infrastructure for clinical care and infection prevention in post–acute care and long-term care settings as compared to acute care hospitals.

Nicola Thompson, PhD, Epidemiologist, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, discusses the lack of data on the burden of healthcare-associated infections in US nursing homes.

Emily Heil, PharmD, BCPS-AQ ID, assistant professor at the University of Maryland School of Pharmacy, describes what the ideal antibiotic stewardship team would look like.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her findings regarding patients treated with ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections and carbapenem-resistant Pseudomonas infections.

Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, discusses how the model of prenatal care centering works.

David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, Augusta University, discusses Zika virus in indigenous populations.

Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains the bactericidal behavior of TXA709, a new drug to treat MRSA infections.

Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.

Annelies Wilder-Smith, MD, PhD, professor at Lee Kong Chian School of Medicine in Singapore, examines the effectiveness of personal protection against Zika, Dengue, and Chikungunya viruses.

Jean-Paul Gonzalez, MD, PhD, Deputy Director, Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Kansas State University, Adjunct Professor, Kansas State University, discusses the Zika virus from a historical perspective.

Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, discusses the social stigma surrounding Zika- and HIV-positive women.

David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, explains how the Zika virus pandemic has brought about a new form of research sharing.

Adriano Schneider, MS, PhD Candidate, Bioinformatics and Genomics, UNC Charlotte, maps the evolution of the Zika virus.

Carmen Zorrilla, MD, professor of obstetrics and gynecology, University of Puerto Rico, School of Medicine, explains her study which stress, depression, and anxiety levels in pregnant women in Puerto Rico with and without Zika infection.

At The First International Zika Conference, Lenore Pereira, PhD, discussed her research regarding the question of how Zika virus is able to spread from maternal blood to the placenta to reach the fetus.

Lenore Pereira, PhD, professor of Cell and Tissue Biology at University of California, San Francisco, discusses how Zika crosses the placenta.

Annelies Wilder-Smith, MD, PhD, professor at Lee Kong Chian School of Medicine in Singapore, discusses why the Zika virus outbreak in Singapore did not reach such large proportions as those that occurred in the Americas.

Viviane Boaventura, MD, PhD, researcher, Fiocruz-Bahia, Gonçalo Moniz Institute, Brazil, discusses her research regarding impaired hearing function due to congenital Zika syndrome.

Alice Panchaud, PharmD, PhD, clinical pharmacist and pharmacoepidemiologist, CHUV, Lausanne University Hospital, Switzerland, explains how data sharing may be used to answer important questions regarding congenital Zika syndrome.

Matthew Aliota, PhD, research scientist, University of Wisconsin, Pathobiological Sciences, explains why the mechanism behind how Wolbachia blocks Dengue virus transmission is not yet fully understood.

Marta G. Cavalcanti, MD, PhD, physician at Infectious Diseases Clinic, Hospital Universitario Clementino Fraga Filho, UFRJ, Brazil, discusses how the period of RNA shedding correlates with the severity of complications associated with mono- or coinfection in Zika patients.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her research on the efficacy of ceftazidime-avibactam against infections caused by gram-negative organisms.

Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, discusses the social and economic implications of methicillin-resistant Staphylococcus aureus.

Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains why MRSA is especially dangerous, and the effectiveness of the team’s new drug, TXA079.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains how his research can assess clinical well-being of patients with skin and soft tissue infections.

Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.